Abstract:The present study describes the synthesis and biological evaluation of In-111(DOTA-3P-RGD(2)) (DOTA = 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid; 3P-RGD(2) = PEG(4)-E[PEG(4)-c(RGDfK)](2); PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid), In-111(DTPA-3P-RGD(2)) (DTPA = diethylenetriaminepentaacetic acid) and In-111(DTPA-Bn-3P-RGD(2)) (DTPA-Bn = 2-(p-thioureidobenzyl)-diethylenetriaminepentaacetic acid) as potential radiotracers for imaging tumor integrin alpha(v)beta(3) expression in athymic nude mice bearing U87MG glioma xenografts. The aim of the study is to assess the impact of the bifunctional chelator (BFC) (DOTA vs. DTPA or DTPA-Bn) on the biodistribution characteristics of the In-111-labeled 3P-RGD(2). IC50 values of DOTA-3P-RGD(2), DTPA-3P-RGD(2) and DTPA-Bn-3P-RGD(2) were determined to be 1.3 +/- A 0.2, 1.4 +/- A 0.3, 1.3 +/- A 0.3 nM, respectively, against I-125-c(RGDyK) bound to U87MG human glioma cells. Radiotracers were prepared by reacting (InCl3)-In-111 with the RGD peptide conjugates in NH4OAc buffer (100 mM, pH 5.5). For DOTA-3P-RGD(2), successful radiolabeling could be completed by heating the reaction mixture at 100A degrees C for 15-20 min. For DTPA-3P-RGD(2) and DTPA-Bn-3P-RGD(2), the radiolabeling was almost instantaneous at room temperature. The specific activity was similar to 50 mCi/mg (or similar to 100 mCi/mu mol) for In-111(DOTA-3P-RGD(2)) and similar to 200 mCi/mg (or similar to 400 mCi/mu mol) for In-111(DTPA-3P-RGD(2)). The results from biodistribution studies showed that all the three radiotracers have high tumor uptake and excellent tumor-to-background (T/B) ratios up to 4-h postinjection. After that time point, both In-111(DTPA-3P-RGD(2)) and In-111(DTPA-Bn-3P-RGD(2)) showed a much faster tumor washout and poorer T/B ratios than In-111(DOTA-3P-RGD(2)). The tumor uptake of In-111(DOTA-3P-RGD(2)) is integrin alpha(v)beta(3)- and RGD-specific. In-111(DOTA-3P-RGD(2)) is metabolically stable while only similar to 25% of In-111(DTPA-Bn-3P-RGD(2)) remains intact in the feces during 2-h period. On the basis of results from this study, it was concluded that In-111(DTPA-3P-RGD(2)) can be an effective integrin alpha(v)beta(3)-targeted radiotracer if the high-specific activity is required. However, DOTA remains to be the BFC of choice for the development of therapeutic lanthanide radiotracers.

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

A New Cyclic RGD Peptide Dimer for Integrin Αvβ3 Imaging.

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Design and Preparation of Novel RGDyC-PEG-PAMAM Nanoprobe Targeting Integrin αvβ3 Receptor, 131I Labeling and Its Quality Control

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Impact of Bifunctional Chelators on Biological Properties of 111In-Labeled Cyclic Peptide RGD Dimers

Radioiodinated bicyclic RGD peptide for imaging integrin αvβ3 in cancers

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging

Evaluation of<sup>111</sup>In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent

Evaluation Of In-111-Labeled Cyclic Rgd Peptides: Tetrameric Not Tetravalent

18F Labeled RGD‐A7R Peptide for Dual Integrin and VEGF‐targeted Tumor Imaging in Mice Bearing U87MG Tumors

Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

188Re Radiolabeling RGD Peptide and Preliminary Biodistribution Evaluation in Mice Bearing S180 Tumors

Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed α v β 3 Integrin Receptors in Non-Small-Cell Lung Cancer

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

Tumor uptake of the RGD dimeric probe99mTc-G3-2P 4-RGD2 is correlated with integrin αv/β 3 expressed on both tumor cells and neovasculature

Impact Of Bifunctional Chelators On Biological Properties Of In-111-Labeled Cyclic Peptide Rgd Dimers